What is the recommended length and dose for vaginal brachytherapy in carcinoma (ca) endometrium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vaginal Brachytherapy Recommendations for Endometrial Cancer

For vaginal brachytherapy in endometrial carcinoma, the target should be limited to the upper vagina with a dose of 7 Gy × 3 fractions prescribed at 0.5 cm depth or 6 Gy × 5 fractions prescribed to the vaginal surface when used alone. 1

Target Length and Location

  • The target for vaginal brachytherapy after hysterectomy should be limited to the upper vagina only 1
  • The most common vaginal length treated is 4 cm according to survey data of radiation oncologists 2
  • Treatment should be directed at the vaginal cuff, which is the most common site of local recurrence 3

Dose Recommendations

For High-Dose Rate (HDR) Vaginal Brachytherapy Alone:

  • 7 Gy × 3 fractions prescribed at a depth of 0.5 cm from the vaginal surface 1
  • OR 6 Gy × 5 fractions prescribed directly to the vaginal surface 1

For HDR Vaginal Brachytherapy as a Boost After External Beam Radiation Therapy (EBRT):

  • 4-6 Gy × 2-3 fractions prescribed to the vaginal mucosa 1
  • More specifically, 5-6 Gy × 2 fractions to the vaginal mucosa is commonly used 1

Technical Considerations

  • The dose should be prescribed to either the vaginal surface or at a depth of 0.5 cm from the vaginal surface, depending on the chosen regimen 1
  • The largest diameter applicator that comfortably fits should be selected to ensure close mucosal apposition 4
  • Three-dimensional planning is used by most practitioners (83.2%), typically for the first fraction only 2
  • Optimization points should be placed at both the apex and lateral vagina for optimal dose distribution 2

Clinical Considerations

  • Lymph node dissection status and number of nodes removed influence treatment decisions for most practitioners 2
  • Vaginal brachytherapy alone is appropriate for high-intermediate risk disease, while high-risk patients may benefit from additional pelvic external beam radiation therapy 3
  • Patients treated with vaginal brachytherapy are prone to vaginal stenosis, which can impair sexual function; vaginal dilators can be used starting 2-4 weeks after treatment completion 1

Dosimetric Considerations

  • Surface prescription provides more uniform doses at all depths in the target volume, whereas 0.5-cm depth prescription creates larger dose variations at the cylinder surface 5
  • Dosimetric uncertainty increases significantly (>30%) with shorter tip space, so adequate coverage of the vaginal apex is essential 5
  • Extreme hot (>150%) and cold spots (<60%) can occur if no optimization points are placed at the curved end of the applicator 5

Following these evidence-based recommendations for vaginal brachytherapy in endometrial cancer will help ensure optimal local control while minimizing treatment-related toxicity.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.